Kurma Partners is a Paris-based healthcare venture capital firm founded in 2009 and affiliated with Eurazeo, one of Europe's largest listed investment groups. The firm manages over €1 billion in assets and has raised four successive healthcare funds, with BioFund IV closed at €215 million as its largest to date. Kurma focuses exclusively on European healthcare innovation, investing across therapeutic biotech, medical technology, and diagnostics, with a team of 25 professionals operating from Paris and Munich.
Kurma Partners invests in early-stage European healthcare and life sciences companies, with a focus on innovative therapeutics, medical technology, and diagnostics. The firm looks for companies where scientific rigor and clinical relevance intersect with a clear path to patient impact and commercial viability. Kurma has a particular strength in the French and German biotech ecosystems, though it invests across Europe. The fund's healthcare mandate is specifically focused on drug development, medical devices, and diagnostics with strong biological or clinical foundations.
BioFund IV is Kurma's fourth healthcare fund, closed at €215 million. The fund has backed 11 companies so far, with approximately 20 investments planned across its lifecycle. LPs include Eurazeo (the anchor), CSL, the European Investment Fund (EIF), and Bpifrance, making the fund one of the most institutionally credentialed European healthcare vehicles of its vintage.
BioFund IV continues Kurma's strategy of leading early-stage rounds in European biotech and medtech, providing capital through clinical proof-of-concept phases where de-risking of scientific and regulatory uncertainty is the primary value creation lever.
Leadership
Thierry Laugel and Rémi Droller serve as Managing Partners of Kurma Partners. Together, they lead a team of 25 investment and operational professionals across the Paris and Munich offices. The team's scientific and medical credentials are deep, reflecting the firm's thesis that investing in therapeutic and diagnostic innovation requires genuine domain expertise, not just financial judgment.
Investment Strategy
Kurma leads early-stage rounds in European biotech, medtech, and diagnostics companies, typically from pre-clinical through Series A or B. The firm provides capital designed to carry companies through scientific and clinical de-risking milestones, including proof-of-concept data and early regulatory filings. Given Eurazeo's backing, Kurma has the capacity for meaningful follow-on investment as portfolio companies progress through development. The Paris and Munich presence gives the team direct access to major European research institutions, hospital networks, and pharmaceutical partnerships.
Notable Investments
BioFund IV's portfolio includes early-stage European biotech and medtech companies:
Other
Kurma Partners is one of the most established dedicated healthcare VC firms in France and one of the few with genuine scale across both Paris and Munich. The Eurazeo affiliation provides credibility with pharma corporates and institutional LPs alike, and the EIF backing reflects European institutional confidence in the team's track record. For European biotech and medtech founders seeking a lead investor with deep scientific expertise, a strong track record across four funds, and institutional LP backing, Kurma is among the most relevant options on the continent.
France
